UtiPro Plus AF
$40.00Current price is: $40.00. Original price was: $43.00.
UtiPro Plus AF is an innovative oral capsule designed to control and prevent urinary tract infections (UTIs) caused by pathogens such as E. coli. Unlike standard treatments, UtiPro Plus AF acts simultaneously at two sites: the intestine and the bladder. By creating a protective barrier in the gut and acidifying the urine, it helps relieve painful symptoms of acute cystitis and significantly reduces the risk of recurring infections.
Product Description
Urinary Tract Infections (UTIs) and cystitis can be painful, disruptive, and frustratingly recurrent. UtiPro Plus AF offers an advanced, dual-action approach to managing these infections. It is a medical device intended for the control and prevention of UTIs produced by pathogens such as E. coli and other gram-negative bacteria.
How Does UtiPro Plus AF Capsules Work?
Most UTIs originate in the intestine, where bacteria migrate to the urinary tract. UtiPro Plus AF is unique because it addresses the infection at both the source and the site of symptoms:
Intestinal Barrier: It contains Xyloglucan (hemicellulose) and Gelose, which form a mechanical film in the intestinal lumen. This prevents the contact of pathogens with the intestinal mucosa, effectively stopping the proliferation and spread of bacteria to the urinary tract.
Bladder Protection: The formula includes Hibiscus and Propolis, which help acidify the urine. This creates an environment in the bladder that is hostile to bacterial growth, limiting the infection and soothing local symptoms.
Why Choose UtiPro Plus AF Capsules ?
This “Advanced Formula” (AF) is designed for both acute attacks and long-term prevention.
Acute Cystitis: When taken at the first sign of symptoms, it helps alleviate pain, burning, and urgency.
Recurrent Infections: For those who suffer from frequent UTIs, UtiPro Plus AF acts as a preventative measure, breaking the cycle of reinfection by controlling the bacterial population in the gut.



Reviews
There are no reviews yet.